Revisiting the correlate of reduced HIV infection risk in the Rv144 vaccine trial
S Zolla-Pazner, PB Gilbert - Journal of Virology, 2019 - Am Soc Microbiol
Journal of Virology, 2019•Am Soc Microbiol
The RV144 vaccine trial is the only clinical study to have shown a modest but statistically
significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the
level of V1V2-specific antibodies as a correlate of reduced infection risk are still
controversial despite many papers supporting and expanding the initial study. We address
these controversies and summarize active-immunization and passive-immunization
experiments in nonhuman primates that support the initial finding.
significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the
level of V1V2-specific antibodies as a correlate of reduced infection risk are still
controversial despite many papers supporting and expanding the initial study. We address
these controversies and summarize active-immunization and passive-immunization
experiments in nonhuman primates that support the initial finding.
Abstract
The RV144 vaccine trial is the only clinical study to have shown a modest but statistically significant decrease in HIV infection risk. RV144 and the subsequent studies identifying the level of V1V2-specific antibodies as a correlate of reduced infection risk are still controversial despite many papers supporting and expanding the initial study. We address these controversies and summarize active-immunization and passive-immunization experiments in nonhuman primates that support the initial finding.
American Society for Microbiology